Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | CCR9 | P51686 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | GABRE | P78334 | 1/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12653216 | 0.86 | IRAK4 (0.45) | IRAK4IDO1TDO2LMNAALDH1A1 | |
| SCHEMBL12165506 | 0.82 | TSHR (0.52) | MAPTLMNAGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL12165534 | 0.80 | RECQL (0.60) | IRAK4MAPTIDO1TDO2MAP2 | |
| SCHEMBL11630143 | 0.79 | GABRP (0.61) | MAPTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL17580571 | 0.78 | P2RX3 (0.41) | IRAK4SMN1; SMN2ALDH1A1KDM4ECYP2C19 | |
| SCHEMBL10288032 | 0.78 | IRAK4 (0.44) | IRAK4MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7088362 | 0.76 | IRAK4 (0.72) | IRAK4IDO1TDO2LMNAALDH1A1 | |
| SCHEMBL11457524 | 0.75 | MAPT (0.62) | MAPTLMNAGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL12165544 | 0.74 | MRGPRX1 (0.51) | MAPTLMNAGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL1808043 | 0.72 | MRGPRX1 (0.53) | MAPTLMNAGAASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493305-B1 | 2-AMINOINDOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA | GENZYME CORP (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | PNMT, AADAT, INMT | IRAK4 3702/4885MAPT 621/4885CCR9 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.